CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled / 33 target
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03629340
NCT03629340Phase 2CompletedOn Track (0.4/mo)Completion was 4mo ago
CompareCT.gov

Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction

University of California, San Francisco·interventional·Posted Aug 14, 2018·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Metformin and Placebo oral capsule for Pulmonary Hypertension and Heart Failure. Completed, enrolled 33 participants across 2 sites.

Detailed Summary

The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension, Heart Failure
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 14, 2018
Enrollment StartFeb 26, 2019
Primary CompletionFeb 27, 2026
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 7.9 years ago

Arms & Interventions

Drug: Metforminexperimental

500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks

Drug: Metformin
Placebo Oral Capsuleplacebo_comparator

Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks

Drug: Placebo oral capsule

Interventions

Metformindrug

500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks

Placebo oral capsuledrug

Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks